华大基因配股据报获国家开发投资集团旗下风投认购
《路透》报道,中国基因企业华大基因获中国政府投资。
公司旗下深圳上市公司透过配股集资逾3亿美元,中国国家开发投资集团(SDIC)於2月1日向深圳证券交易所提交的文件作有关披露。该集团为中国中央政府全资企业,集中投资战略性行业,包括生物科技、人工智能及关乎国家利益的基建。
报道指,SDIC旗下风投管理的一个基金,动用2亿人民币购入140万股华大基因股份。该风投称投资目的为推动中国透过改善医疗及应付新冠疫情消费穷困,又指防疫控疫是社会利益的一种。另外,中国国营券商华泰证券及招商证券亦入股华大基因,华泰证券更成为华大基因第五大股东。
华大基因表示,集资所得将用作缓解运作资本压力,提升储存基因数据能力及建立生物样本银行。
华大基因於新冠疫情下向全球供应百万计测试,於中国运作大型基因资料库,并与全球健康企业和大学有基因排序合约。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.